ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

Post author:
Post published:October 1, 2024
Post category:uncategorized

Université de Montréal gains access to ERS Genomics’ CRISPR/Cas9 patents, launching platforms for genome-wide screening and fostering research collaborations.

Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.

Helpful Links

Subscribe To Us

By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy

UPCOMING EVENTS

You Might Also Like

Study: Extending diabetic eye screen to 2 years could risk critical treatment delays and sight loss

Multidisciplinary approach improves quality of life in functional movement disorders

Universal consensus definition unlocks research advancements for critically ill children worldwide

Helpful Links

Subscribe To Us